The global clinical trials activity saw a decrease of 8.3% in Q1 2022, when compared with the rolling average of the last four quarters (Q1 2021 to Q4 2021), according to GlobalData.
Of the overall activity, industry sponsored trials accounted for a 48.1% share in Q1 2022, marking a decrease of 0.8% in the total share when compared with the four-quarter average.
Go deeper with GlobalData
Non-industry sponsored trials accounted for a 51.9% share of all the clinical trials globally in Q1 2022, marking an increase of 0.8% in the overall share when compared with the four-quarter average.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry and non-industry sponsored clinical trials in Q1 2022
See Also:
Oncology was the leading therapy area for industry sponsored clinical trials in Q1 2022, accounting for a 30.7% share of all trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis was followed by the following therapy areas: Infectious Disease with a 15.2% share, Central Nervous System with a 14.3% share, Metabolic Disorders with a 7.4% share and Cardiovascular with a 6.1% share.
In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.6% share, followed by Infectious Disease with a 17.1% share, Central Nervous System with a 14.2% share, Metabolic Disorders with a 7.8% share, and Cardiovascular with a 7.7% share.
| Industry sponsored trials activity: 4-Quarter Avg. vs Q1 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q1 2022 | Activity |
| Oncology | 27.6% | 30.7% |  |
| Infectious Disease | 17.1% | 15.2% |  |
| Central Nervous System | 14.2% | 14.3% | |
| Metabolic Disorders | 7.8% | 7.4% | |
| Cardiovascular | 7.7% | 6.1% | |
| Immunology | 5.5% | 5.7% | |
| Gastrointestinal | 6.7% | 5.3% | |
| Respiratory | 5.7% | 4.7% | |
| Dermatology | 4.6% | 4.4% | |
| Musculoskeletal Disorders | 4.1% | 4.1% | |
| Hematological Disorders | 2.7% | 3.3% | |
| Ophthalmology | 2.9% | 3.0% | |
| Genito Urinary System And Sex Hormones | 2.6% | 2.7% | |
| Genetic Disorders | 1.7% | 1.8% | |
| Women’s Health | 1.9% | 1.4% | |
| Ear Nose Throat Disorders | 1.5% | 1.3% | |
| Hormonal Disorders | 0.7% | 0.6% | |
| Male Health | 1.0% | 0.4% | |
| Mouth and Dental Disorders | 0.6% | 0.4% | |
| Nutritional Disorders | 0.3% | 0.3% | |
| Non Malignant Disorders | 0.2% | 0.2% | |
Central Nervous System was the leading therapy area for non-industry sponsored clinical trials in Q1 2022, accounting for a 25.5% share of all trials.
This was followed by the following therapy areas: Oncology with a 22.0% share, Infectious Disease with a 12.5% share, Cardiovascular with a 9.8% share, and Gastrointestinal with a 6.2% share.
In the last four quarters, Central Nervous System System held a lead over others for non-industry sponsored clinical trials with an average share of 24.1%, followed by Oncology with a 23.3% share, Infectious Disease with a 15.0% share, Cardiovascular with an 8.9% share, and Gastrointestinal with a 6.5% share.
| Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q1 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q1 2022 | Activity |
| Central Nervous System | 24.1% | 25.5% | |
| Oncology | 23.3% | 22.0% | |
| Infectious Disease | 15.0% | 12.5% | |
| Cardiovascular | 8.9% | 9.8% | |
| Gastrointestinal | 6.5% | 6.2% | |
| Metabolic Disorders | 5.3% | 6.1% | |
| Musculoskeletal Disorders | 5.0% | 5.3% | |
| Women’s Health | 4.5% | 4.2% | |
| Respiratory | 4.3% | 3.8% | |
| Immunology | 3.3% | 3.4% | |
| Hematological Disorders | 2.9% | 3.3% | |
| Genito Urinary System And Sex Hormones | 2.8% | 2.9% | |
| Dermatology | 2.9% | 2.4% | |
| Mouth and Dental Disorders | 2.5% | 2.4% | |
| Ophthalmology | 1.9% | 1.9% | |
| Ear Nose Throat Disorders | 1.1% | 1.1% | |
| Hormonal Disorders | 0.8% | 1.1% | |
| Genetic Disorders | 0.6% | 0.6% | |
| Male Health | 0.7% | 0.6% | |
| Nutritional Disorders | 0.7% | 0.5% | |
| Non Malignant Disorders | 0.3% | 0.3% | |
Top regions in industry and non-industry sponsored clinical trials activity in Q1 2022
Asia-Pacific held the top position for industry sponsored clinical trials activity in Q1 2022 with a 48.0% share, compared to 54.6% in the last four quarters.
North America stood at second place with a 36.0% share in Q1 2022, over 31.3% in the last four quarters, followed by Europe with a 28.3% share in Q1 2022, as against 28.5% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 85.5% share in industry sponsored clinical trials in Q1 2022 when compared with an 83.8% average recorded in the last four quarters. Multinational trials accounted for a 14.5% share in Q1 2022, as against the four-quarter average of 16.2%.
Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q1 2022 with a 49.8% share, over 50.8% in the last four quarters.
North America held the second position with a 20.5% share in Q1 2022, over 16.4% in the last four quarters, followed by Europe with a 15.2% share in Q1 2022, as against 14.5% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held a 98.8% share for non-industry sponsored clinical trials in Q1 2022, compared to 98.9% in the last four quarters. Multinational trials accounted for a 1.2% share in Q1 2022, as against 1.1% in the last four quarters.
Industry and non-industry sponsored clinical trials by Phase in Q1 2022
Phase II trials outnumbered all other studies with a 39.4% share for industry sponsored trials in Q1 2022, compared to a 35.0% average in the last four quarters.
The share of Phase I trials stood at 31.6% in Q1 2022, as against the four-quarter average of 37.0%. Phase III trials held an 18.3% share in Q1 2022, registering an increase of 2.2% over the last four quarters average, followed by Phase IV trials with a 10.7% share in Q1 2022, as against the four-quarter average of 11.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials outnumbered all other trials with a 47.5% share for non-industry sponsored clinical trials in Q1 2022, compared to 41.5% in the last four quarters.
Phase IV trials stood at second place with a 20.4% share in Q1 2022, compared to 23.0% in the last four quarters. Phase I trials held a 17.2% share in Q1 2022, as against 16.0% in the last four quarters, followed by Phase III trials with a 15.0% share in Q1 2022 over a 19.4% average recorded in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
